

1 **Title: Use of illness severity scores to predict mortality in interstitial lung disease**
2 **patients hospitalised with acute respiratory deterioration**

3 Rachel L Williams^{1,2†}, Catherine Hyams^{1,3,4,5†}, Joe Robertshaw^{1,3}, Maria Garcia Gonzalez^{4,5},
4 Zsuzsa Szasz-Benczur⁴, Paul White⁶, Nick A Maskell¹, Adam Finn⁴ and Shaney L Barratt^{1,3}
5 on behalf on the AvonCAP Research Group

6

7 ¹ Academic Respiratory Unit, University of Bristol, North Bristol NHS Trust, Southmead,
8 Bristol, BS10 5NB

9 ² Research and Innovation, North Bristol NHS Trust, Southmead, Bristol BS10 5NB

10 ³ Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Southmead, Bristol
11 BS10 5NB

12 ⁴ Bristol Vaccine Centre, Schools of Population Health Sciences and Cellular and Molecular
13 Medicine, University of Bristol, Bristol, BS2 8AE

14 ⁵ Vaccine and Testing Team, UHBW NHS Trust, Bristol

15 ⁶ University of the West of England, Bristol, BS16 1QY

16 [†] These authors contributed equally to this work

17

18 **Correspondence to:** Dr Shaney Barratt,
19 Bristol Interstitial Lung Disease Service,
20 North Bristol NHS Trust, Southmead Hospital,
21 Bristol BS10 5NB, UK
22 shaney.barratt@nbt.nhs.uk

23

24 **Funding:** The AvonCAP study is an investigator-led University of Bristol
25 sponsored study which was designed and implemented collaboratively
26 with Pfizer, Inc. which also funded the study. For the current
27 manuscript, Pfizer staff did not play any part in data collection,
28 analysis plan, data analysis or manuscript preparation

29 **ABSTRACT**

30 **Introduction**

31 Hospitalisations relating to acute respiratory deteriorations (ARD) in Interstitial Lung
32 Disease (ILD) have poor outcomes. Factors predicting adverse outcomes are not fully
33 understood and data addressing the use of illness severity scores in prognostication are
34 limited.

35

36 **Objective**

37 To validate the use of CURB-65 and NEWS-2 severity scores to predict mortality following
38 ARD-ILD hospitalisation.

39

40 **Methods**

41 A dual-centre prospective observational cohort study of all adults (≥ 18 y) hospitalised with
42 ARD-ILD in Bristol, UK (n=179). Gender-Age-Physiology (GAP), CURB-65 and NEWS-2
43 scores were calculated for each eligible admission.

44

45 Receiver operating characteristics (ROC) curve analysis was used to quantify the strength of
46 discrimination for NEWS-2 and CURB-65 scores. Univariable and multivariable logistic
47 regression analyses were performed to explore the relationship between baseline severity
48 scores and mortality.

49

50 **Results**

51 GAP showed some merit at predicting 30-day mortality (AUC=0.64, $P=0.015$); whereas
52 CURB-65 showed modest predictive value for in-hospital (AUC=0.72, $P<0.001$) and 90-day
53 mortality (AUC=0.67, $P<0.001$). NEWS-2 showed higher predictive value for in-hospital

54 (AUC=0.80, $P<0.001$) and 90-day mortality (AUC=0.75, $P<0.001$), with an optimal derived
55 cut-off ≥ 6.5 found to be sensitive and specific for predicting in-hospital (83% and 63%) and
56 90-day (73% and 72%) mortality. In exploratory analyses, GAP score addition improved the
57 predictive ability of NEWS-2 against 30-day mortality and CURB-65 across all time-periods.

58

59 **Conclusion**

60 NEWS-2 has good discriminatory value for predicting in-hospital mortality and moderate
61 discriminatory value for predicting 90-day mortality. The optimal NEWS-2 cut-off value
62 determined was the same as in a previous retrospective cohort, confirming the NEWS-2 score
63 shows promise in predicting mortality following ARD-ILD hospitalisation.

64 **KEY MESSAGES**

65 **What is the key question?**

- 66 - Can NEWS-2 and CURB-65 be used to predict inpatient mortality in a cohort of
67 patients with acute respiratory deterioration on a background of known interstitial
68 lung disease?

69

70 **What is the bottom line?**

- 71 - The NEWS-2 score shows high sensitivity and specificity in predicting both 90-day
72 and in-hospital mortality in patients hospitalised with ARD-ILD
73 - Whilst the CURB-65 score showed high sensitivity for predicting mortality, there was
74 a low specificity, and did not add value to the predictive ability of the NEWS-2 score.

75

76 **Why read on?**

- 77 - This analysis included 179 patients from two study sites and provides, for the first
78 time, prospective evidence for utilising NEWS-2 and CURB-65 as tools to predict in-
79 hospital and post hospitalisation morbidity.

80 INTRODUCTION

81 Idiopathic pulmonary fibrosis (IPF) is considered the archetypal chronic progressive fibrotic
82 Interstitial Lung Disease (ILD), which can have an unpredictable clinical course punctuated
83 by sudden, severe acute respiratory deteriorations (ARD). ARD related hospitalisations in
84 IPF patients are associated with poor patient outcomes, posing a significant burden on
85 healthcare services.¹⁻⁴ ARD-IPF are categorised into parenchymal and extra-parenchymal
86 causes within a conceptual framework.¹ Acute exacerbation (AE), defined within this
87 framework describes rapid respiratory deterioration associated with new widespread
88 parenchymal ground glass opacification (with or without consolidation) on the background of
89 established fibrosis and is not fully explained by fluid overload or cardiac failure. Mortality
90 associated with AE-IPF is high;^{1,5} although, factors predicting adverse outcomes are not fully
91 understood. Whilst originally described in IPF, both ARD and AE are increasingly
92 considered to be features of other fibrosing ILDs; although, their epidemiology and triggers
93 in non-IPF ILDs are less well understood, with no randomised controlled trials examining
94 optimal management.⁵

95

96 The emergence of SARS-CoV-2 and resultant pandemic have severely impacted healthcare
97 provision, with ILD patients at increased risk of severe COVID-19 disease, possibly
98 attributable to immunosuppressive treatment in addition to their chronic lung changes.⁶⁻⁸

99 Ensuring appropriate healthcare resource allocation and usage, especially with the significant
100 ILD disease burden, may be aided by validated illness scores as predictors of mortality. The
101 CURB-65 score was validated against 30-day mortality in pneumonia,⁹ and subsequently
102 validated against other conditions including sepsis. The National Early Warning Score-2
103 (NEWS-2) is used throughout UK hospitals to rapidly identify patients at risk of

104 deterioration,¹⁰ and also to predict in-hospital mortality. There are few data on the use of
105 illness severity scores to predict short to medium term outcomes following admission.^{11–13}

106

107 Our previous single-centre, retrospective, observational cohort study of 172 IPF patients
108 admitted with ARD, supported the use of CURB-65 and NEWS-2 illness severity scores to
109 predict in-hospital and 90-day mortality.⁴ ARD-IPF mortality was high irrespective of cause,
110 in-line with mortality estimates from other published cohorts;³ however, data also suggests
111 AE-IPF mortality is higher compared to other parenchymal causes of ARD.¹⁴

112

113 The AvonCAP prospective observational study of acute lower respiratory tract disease
114 (aLRTD) provided the opportunity to evaluate CURB-65 and NEWS-2 usage as predictors of
115 mortality in a broad cohort of patients with ARD-ILD hospitalisations following the
116 emergence of SARS-CoV-2. We describe the characteristics of a prospective cohort of
117 patients hospitalised with ARD-ILD, comparing those patients with IPF and non-IPF ILDs
118 and investigating factors associated with worse outcome.

119

120 **METHODS**

121 **Study Design**

122 A prospective, dual-centre observational cohort study undertaken at North Bristol and
123 University Hospitals Bristol and Weston NHS Foundation Trusts, encompassing all
124 secondary care institutions in Bristol, UK, as part of the AvonCAP study. The study was
125 approved by the Health Research Authority East of England Ethics Committee, including use
126 of Section 251 of the 2006 NHS Act approved by the Confidentiality Advisory Group
127 (REC:20/EE/0157, ISRCTN:17354061).

128

129 **Study Subjects**

130 Patients hospitalised with worsening respiratory signs/symptoms between 1st August 2020
131 and 9th November 2021 were screened. Full inclusion and exclusion criteria are available on
132 IRISCTN.¹⁵ Only individuals with a multidisciplinary team (MDT)-confirmed diagnosis of
133 ILD (either pre-existing or arising from the hospitalisation), including but not limited to IPF,
134 were included in this analysis.

135

136 Collection of clinical data was undertaken on all eligible participants using a standardised
137 REDCap proforma¹⁶. Lung Function Tests (LFTs) and 6-min walk test (6MWT) were
138 included if conducted within 6-months of hospitalisation and were not performed specifically
139 for this study. Gender-Age-Physiology (GAP), CURB-65 and NEWS-2 scores were
140 calculated for each hospital admission.^{9,17-19}

141

142 **Case Definitions**

143 The aetiology of ARD-ILD was categorised according to Collard's conceptual framework:

144 (1) Extra-parenchymal causes: pleural effusion, pneumothorax or pulmonary embolism,

145 (2) AE-ILD: diagnosed in accordance with broadened Collard *et al.* revised criteria²⁰ to

146 include all fibrosing ILDs: previous/concurrent ILD, worsening dyspnoea <1 month duration,

147 new bilateral ground-glass opacification (with/without consolidation) on CT imaging,

148 superimposed on background of established fibrosis and not fully explained by cardiac

149 failure/ fluid overload. AE-ILD was further sub-categorised into triggered (clear precipitant)

150 or idiopathic.

151 (3) Not AE-ILD: other parenchymal ARD-ILD causes not attributed to an AE, including:

152 non-pneumonic lower respiratory tract infection (NP-LRTI)/presumed NP-LRTI (defined in

153 the context of a CT not clearly identifying a radiological cause for the deterioration or

154 unchanged CXR (presumed) but CRP>6mg/ml); pneumonia; cardiac failure/fluid overload;
155 disease progression; and, those with non-specific trigger (no radiological cause demonstrated
156 on CT imaging with CRP<6mg/ml; for example: anxiety, symptom control and/or palliation).
157 (4) Not fully classified ARD-ILD: hospitalisation without CT imaging on admission but
158 unaltered chest radiograph and CRP <6mg/ml and no clear trigger.

159

160 **Outcome Measures**

161 The primary outcome was to validate previously determined baseline CURB-65 score ≥ 3.5
162 and NEWS-2 score ≥ 6.5 as predictors of in-hospital mortality⁴ in a broader group of patients
163 with ILD.

164

165 Secondary outcomes were to determine the utility of the GAP score to predict in-hospital, 30-
166 and 90-day mortality rates in patients with ARD-ILD, in addition to determining the overall
167 in-hospital, 30- and 90-day mortality rates for patients with ARD-ILD, hospital length of stay
168 (LOS), thereby highlighting any differences in mortality between IPF and non-IPF ARD
169 cohorts.

170

171 **Statistical Analysis**

172 Categorical data were presented as numbers and proportions (n, %), continuous non-
173 parametric data as medians and interquartile range (IQR). Either log rank test, Fisher's exact
174 test or chi-square test was used where appropriate to analyse differences between groups.

175

176 For the primary analysis, univariable and multivariable logistic regression analyses were
177 performed to explore the relationship between baseline severity scores and mortality. The
178 factors used in the multivariable model were decided *a priori* and were smoking status, GAP

179 score, CURB-65 and NEWS-2 score. Receiver operating characteristic (ROC) curve analysis
180 was used to quantify the strength of discrimination. Previous data suggested cut-offs of
181 CURB-65>3.5 and NEWS-2>6.5, provided Area Under the Receiver Operating Curve
182 (AUROC) estimates of 0.85 and 0.89 respectively, in the prediction of in-hospital mortality in
183 hospitalised ARD-IPF.⁴ Assuming an inpatient mortality rate approximating 20%.⁴ a
184 consecutive sample size of 175 patients would be sufficient to validate an AUROC \geq 0.8 with
185 a lower 95% confidence interval (CI) of the AUROC exceeding a lower acceptability
186 threshold of 0.7.²¹ Power calculations were performed using the proprietary Power Analysis
187 & Sample Size (PASS) software.

188

189 The impact of prognostic factors on survival was computed using a Kaplan-Meier analysis
190 and multivariate Cox proportional hazards model. For all tests, a $P<0.05$ was considered
191 statistically significant. Data were analysed using IBM SPSS v28.0.

192

193

194 **RESULTS**

195 **Patient Demographics**

196 Of the total 132,097 patients \geq 18 years hospitalised in the study period: 179 patients had
197 confirmed ARD with a multidisciplinary diagnosis of ILD (Figure 1A). The median age of
198 patients was 75 years (IQR 72-84), 64% were male and 57% were ex-smokers (Table 1). IPF
199 was the underlying diagnosis of 40% of the cohort, but a broad range of other ILD diagnoses
200 existed, including: unclassifiable ILD (13%), hypersensitivity pneumonitis (HP) (12%), and
201 connective tissue disease associated-ILD (10%) (Table 1). *De novo* presentations with ILD
202 were infrequent (3% ILD admissions). Patients had moderately restrictive disease (median
203 FVC% predicted 75 (IQR 63-91), TLCO 44% (IQR 33-58) and a median GAP score of 4

204 (IQR 3-5), corresponding to GAP stage II. Approximately one third of patients had at least 2
205 or more (31%, n=56) concurrent medical co-morbidities. Overall, vaccination rates were high
206 in the cohort: 75% of patients having received pneumococcal and seasonal influenza
207 vaccination by the time of admission, and 83% of eligible patients (Supplementary Data 1)
208 having received at least one dose of a COVID-19 vaccination prior to admission.

209

210 IPF patients were statistically older than those with non-IPF ILD diagnoses (IPF 81 years vs
211 non-IPF 77 years, $P=0.0068$), more likely to be male (IPF 77% vs non-IPF 55%, Fisher's
212 exact test, $P=0.004$), with lower TLCO % predicted (IPF 38% vs non-IPF 54%, $P=0.0002$)
213 and higher GAP scores (IPF 5 vs non-IPF 4, $P<0.0001$) on hospitalisation. IPF and non-IPF
214 ILD patients had comparable baseline spirometry values (Table 1).

215

216 **Underlying Aetiology**

217 Most (79%) ARD-ILD admissions were due to parenchymal causes other than AE-ILD
218 (Figure 1B). Pneumonia was the most common parenchymal cause (57%, 77/141); the vast
219 majority were community-acquired (83% of pneumonias, n=63), with COVID-19
220 pneumonitis in eleven patients (14%). Other parenchymal causes included cardiac failure
221 (n=21, 15%), NP-LRTI (n=24, 17%, including 3 patients with symptomatic COVID) and
222 disease progression in n=5 (4%). An extra-parenchymal pathology was considered the cause
223 of ARD in 12 patients (7%); 7 with pulmonary embolism, 3 with pleural effusion/empyema,
224 with pneumomediastinum and anaphylaxis in the remaining patients.

225

226 Non-specific triggers of ARD were identified in approximately 10% of patients and these
227 admissions were related to requirements for palliation and symptom control, including
228 anxiety and breathlessness. AE-ILD was rare in this cohort (n=3, 2%) and seen in patients

229 with fibrotic hypersensitivity pneumonitis and IPF. Due to low incidence of AE-ILD we were
230 not able to perform analyses to determine differences between patients admitted with AE-ILD
231 and other parenchymal causes.

232 **Table 1: Characteristics of adults hospitalised with ARD-ILD**

Characteristic	ARD-ILD n = 179	IPF n = 70	Non IPF n = 109	P-value
Male, n (%)	114 (64)	54 (77)	60 (55)	0.0040
Age (years), median (IQR)	79 (72-84)	81 (75-86)	77 (70-83)	0.0068
Smoking Status, n (%)				0.2537
Current	9 (5)	4 (6)	5 (5)	
Ex-smoker	102 (57)	48 (69)	54 (50)	
Never	53 (30)	14 (20)	39 (36)	
Unknown	15 (8)	4 (6)	11 (10)	
Ethnicity, n (%)				0.7566
Caucasian	148 (83)	58 (83)	90 (83)	
Other	11 (6)	6 (9)	5 (5)	
Unknown	20 (11)	6 (9)	14 (13)	
CCI, median (IQR)	5 (4-6)	5 (4-6)	5 (3-6)	0.8765
Aetiology ILD, n (%)				N/A
IPF	70 (39)	70 (39)	-	
Unclassifiable	23 (13)	-	23 (13)	
Hypersensitivity pneumonitis	22 (12)	-	22 (12)	
CTD-ILD	17 (10)	-	17 (10)	
Smoking related ILD	14 (8)	-	14 (8)	
CPFE	9 (5)	-	9 (5)	
NSIP	8 (5)	-	8 (5)	
Sarcoid	6 (3)	-	6 (3)	
Asbestosis	4 (2)	-	4 (2)	
Other □	6 (3)	-	6 (3)	
Baseline PFTs, median (IQR)				
Lung function				
FEV1 % predicted	78 (66-93), n=168	81 (69-93), n=68	75 (63-93), n=100	0.5627
FVC % predicted	75 (63-91), n=168	75 (64-89), n=68	77 (63-96), n=100	0.5324
TLCO % predicted	44 (33-58), n=137	40 (30-46), n=58	54 (37-61), n=79	0.0002
6MWT distance (m)	240 (155-311), n=133	240 (130-290), n=60	245 (168-354), n=73	0.7552
6MWT minimum sats (%)	87 (84-90) n=133	87 (84-89), n=60	87 (84-90), n=73	0.8129
Total GAP score	4 (3-5), n=150	5 (4-6), n=61	4 (3-5), n=89	<0.0001
Admission Severity Scores				
CURB-65, median (IQR)	2 (1-4)	2 (1-4)	1 (1-3)	0.0096
NEWS-2, median (IQR)	6 (3-8)	6 (3-8)	5 (2-8)	0.4246
Respiratory Support, n (%)				
None	20 (11)	10 (14)	10 (9)	0.1382
Oxygen	159 (89)	60 (86)	99 (91)	0.1482
HFNO	20 (11)	8 (11)	12 (11)	1.0000
NIV	8 (4)	5 (7)	3 (3)	0.2123
IMV	1 (1)	0 (0)	1 (1)	0.4033
Treatment, n (%)				
Received antibiotics (>2 days)	139 (78)	53 (74)	86 (79)	0.4391
Received corticosteroids	49 (27)	18 (26)	31 (28)	0.7702
Length of stay, median (IQR)				
Hospitalisation days	6 (3-11)	7 (3-11)	6 (3-11)	0.5451
Mortality, n (%)				
In-hospital mortality	34 (19)	17 (24)	17 (16)	0.1848
30-day mortality	42 (23)	21 (30)	21 (19)	0.0901
90-day mortality	69 (39)	33 (47)	36 (33)	0.0614
Survival days, median (IQR)	59 (10-144), n=101	23 (10-23), n=41	79 (13-144), n=60	0.0417

233 *P*-values represent the result of a Log-rank Test or Fisher's exact test between IPF and non-IPF
234 groups

235
236 □ Other includes lymphocytic interstitial pneumonia, Langerhan's cell histiocytosis, pleuro-
237 parenchymal fibroelastosis, Rosai-Dorfman, organising pneumonia.

238
239 6MWT, 6-minute walk test; ARD, acute respiratory deterioration; CCI, Charlson comorbidity index;
240 CPFE, combined pulmonary fibrosis & emphysema; CTD-ILD, connective tissue disease ILD; GAP,
241 gender, age and physiology score; HFNO, high flow nasal oxygen; ILD, interstitial lung disease; IPF,
242 idiopathic pulmonary fibrosis; IMV, invasive mechanical ventilation; IQR, interquartile range; NIV,
243 non-invasive ventilation NSIP, non-specific interstitial pneumonia; PFTs, pulmonary function tests

244

245

246

247 **Primary Outcome**

248 Over half of all patients hospitalised with an ARD-ILD had a CURB-65 \geq 2 (n=99, 55%) and
249 NEWS-2 \geq 5 (n=114, 64%) on admission. Patients with ARD-IPF had a statistically higher
250 baseline CURB-65 compared to those with non-IPF ARD-ILD diagnoses (median CURB-65
251 2 [IQR 1-4] versus 1 [IQR 1-3], *P*=0.0096), but baseline NEWS-2 scores were comparable
252 (median NEWS-2 6 [IQR 3-8] versus 5 [IQR 2-8] respectively, *P* >0.05) (Table 1).

253

254 GAP score was found to have diminishing utility for in-hospital (AUC=0.604, *P*=0.087) and
255 some merit at 30-days (AUC=0.642, *P*=0.015). CURB-65 showed modest predictive value
256 for in-hospital (AUC=0.715, *P*<0.0001) and 90-day mortality (AUC=0.672, *P*<0.0001), with
257 the optimal derived cut-off CURB-65 \geq 2.5 in our previous study⁴ had high specificity (75,
258 88% respectively) but low sensitivity (57, 46% respectively) (Table 2). The optimal derived
259 cut-off for CURB-65 in this cohort was 3.5. The NEWS-2 showed higher predictive value for
260 in-hospital (AUC=0.803, *P*<0.0001) and 90-day mortality (AUC=0.751, *P*<0.0001). The
261 optimal cut-off for NEWS-2 \geq 6.5 was found to have high sensitivity (73%) and specificity
262 (72%) for predicting 90-day mortality, in contrast to high sensitivity (83%) and moderate
263 specificity (63%) for predicting in-hospital mortality (Table 2).

264

265 As the CURB-65 score correlated moderately to NEWS-2 score ($R=0.552$, $P<0.0001$), the
266 combined ability of these two scores to predict mortality was assessed (Table 2). NEWS-2
267 retained significance to predict 90-day and in-hospital mortality after allowing for the effect
268 of CURB-65 score (OR 1.34, $P<0.0001$, and OR 1.47, $P<0.0001$, respectively); however,
269 CURB-65 was no longer a significant predictor after controlling for NEWS-2 for 90-day (OR
270 1.34, $P=0.1648$) or in-hospital mortality (OR 1.423, $P=0.1791$) (Supplementary Data 3). The
271 addition of the GAP score improved the ability of the CURB-65 score to predict mortality
272 (Table 2), with both GAP and CURB-65 retaining significance in each other's presence. In
273 contrast, the GAP score only improved the ability of the NEWS-2 score to predict 30-day
274 mortality.

275

276 **Secondary Outcomes**

277 The median length of stay for patients admitted with an ARD-ILD was 6 days, but variability
278 was observed across the cohort (IQR 3-11 days). Small numbers of patients received
279 advanced respiratory support during their admission ($n=29$, 16%) although supplementary
280 oxygen was frequently prescribed ($n=159$, 89%) (Table 1). ARD-ILD associated mortality
281 was high; 20% of hospitalisations resulted in death, with 30- and 90-day mortality following
282 admission of 24% and 38% ($n=68$) respectively (Table 1). Survival curve analysis indicated
283 that patients admitted with ARD-IPF had higher in-hospital and 90-day mortality than
284 patients with non-IPF-ARD (Figure 2). Univariate Cox regression analysis indicated that
285 increasing NEWS-2 score was associated with higher mortality risk in-hospital and at 90-
286 days; however, increased admission CURB-65 scores were not associated with an increased
287 mortality risk (Table 3). Neither were higher admission CURB-65 nor NEWS-2 scores found
288 to be associated with increased hazard of in-hospital mortality.

289 **Table 2: Outcomes of ROC curve analysis for evaluating optimal cut-off values for**
 290 **CURB-65, NEWS-2 and GAP scores, correlating with ARD-ILD mortality**
 291 Evaluation of the receiver operator curve (ROC) curve analysis for CURB-65, NEWS-2 and
 292 GAP scores correlate with 30- and 90-day mortality, in addition to in-hospital mortality.
 293

	AUC	95% CI	P-value	Decision Point	Sensitivity	Specificity	Youden's Index (J)
SINGLE DISEASE SEVERITY SCORES							
CURB-65							
In-hospital mortality	0.715	0.620-0.810	<0.0001	3.5	0.200	0.965	0.17
				2.5	0.571	0.746	0.32
30-day mortality	0.650	0.553-0.746	0.0021	1.5	0.476	0.737	0.21
90-day mortality	0.672	0.591-0.753	<0.0001	3.5	0.130	0.973	0.10
				2.5	0.464	0.882	0.25
NEWS-2							
In-hospital mortality	0.803	0.731-0.875	<0.0001	6.5	0.829	0.634	0.46
30-day mortality	0.750	0.669-0.831	<0.0001	6.5	0.762	0.642	0.40
90-day mortality	0.751	0.680-0.822	<0.0001	6.5	0.725	0.718	0.44
GAP							
In-hospital mortality	0.604	0.491-0.717	0.0869	4.5	0.607	0.554	0.16
30-day mortality	0.642	0.541-0.744	0.0151	3.5	0.871	0.353	0.22
90-day mortality	0.564	0.471-0.658	0.1887	4.5	0.545	0.568	0.11
COMBINATION DISEASE SEVERITY SCORES							
CURB-65 and NEWS-2							
In-hospital mortality	0.805	0.731-0.879	<0.0001	0.157	0.857	0.620	0.48
30-day mortality	0.681	0.589-0.822	<0.0001	0.225	0.624	0.681	0.40
90-day mortality	0.757	0.687-0.827	<0.0001	0.392	0.710	0.682	0.39
CURB-65 and GAP							
In-hospital mortality	0.764	0.671-0.856	<0.0001	0.207	0.679	0.739	0.41
30-day mortality	0.761	0.677-0.846	<0.0001	0.140	0.903	0.504	0.41
90-day mortality	0.727	0.646-0.809	<0.0001	0.335	0.673	0.663	0.34
NEWS-2 and GAP							
In-hospital mortality	0.802	0.745-0.895	<0.0001	0.239	0.679	0.802	0.48
30-day mortality	0.810	0.732-0.888	<0.0001	0.177	0.839	0.639	0.48
90-day mortality	0.752	0.675-0.828	<0.0001	0.342	0.782	0.642	0.43

294

295 AUC, area under curve; CI, confidence interval; GAP, Gender, Age, Physiology Score; ROC,
 296 receiver operator characteristics. ROCs are provided within Supplementary Data 2 and 3.

297

298

299
300
301
302
303

Table 3: Association of baseline patient factors with in-hospital mortality and 90-day mortality following hospitalisation with ARD-ILD
Cox proportional hazard regression univariate analysis

Analysis	Factor	Wald	HR	P-value	95% CI
In hospital mortality	GAP score	0.365	1.089	0.5452	0.826-1.435
	Smoking Status	3.102	2.022	0.0778	0.924-4.428
	CURB-65 score	3.163	1.565	0.0747	0.955-2.562
	NEWS-2 score	3.841	1.188	0.0501	1.000-1.411
90-day mortality	GAP score	1.020	0.773	0.3132	0.469-1.274
	Smoking Status	2.016	1.676	0.1558	0.822-3.419
	CURB-65 score	1.089	0.753	0.2967	0.442-1.283
	NEWS-2 score	4.251	1.231	0.0391	1.010-1.501

304
305

CI, confidence interval; GAP, Gender, Age, Physiology Score; HR, hazard ratio.

306 **DISCUSSION**

307 The identification of patients with poor prognosis among those with ARD-ILD remains a
308 significant challenge and there are limited data addressing the utility of illness severity scores
309 to predict outcomes of these patients. This prospective study suggests that, as a predictor of
310 mortality in this patient cohort, the NEWS-2 score has good discriminatory value for
311 predicting in-hospital mortality and moderate discriminatory value for predicting 90-day
312 mortality in patients with ARD-ILD. To our knowledge, this is the first prospective evidence
313 for utilising NEWS-2 as a tool to predict in-hospital and post hospitalisation morbidity. A
314 previous retrospective cohort study conducted at one of the study hospitals found that both
315 NEWS-2 and CURB-65 risk stratification tools were independent predictors of mortality in
316 patients with IPF.⁴ The current study therefore confirms the findings of this previous
317 retrospective cohort⁴ and hence NEWS-2 may represent a simple tool to help prognostication.
318 Notably, the optimal derived cut-off value for NEWS-2 in predicting mortality across
319 inpatient, 30- and 90-days was NEWS-2 ≥ 6.5 , the same in both this prospective patient
320 cohort and our previously reported retrospective cohort.⁴

321

322 The CURB-65 score was found to have little additional benefit for predicting mortality, either
323 as an individual predictor or when used in exploratory analyses with NEWS-2. Furthermore,
324 we found that CURB-65 was able to predict both 90-day and in-hospital mortality in ARD-
325 ILD with high specificity but low sensitivity, in keeping with previous data from our IPF
326 cohort⁴. Aligning with these findings, Yamazaki *et al* found that CURB-65, Pneumonia
327 Severity Index (PSI) and Sequential Organ Failure Assessment (qSOFA) were all predictive
328 of inpatient mortality from pneumonia in a retrospective study of 79 patients with IPF.²² In
329 that study, the optimal CURB-65 cut-off value was ≥ 3.0 , differing slightly from the value
330 derived in our previous retrospective IPF cohort,⁴ but contrasting with the optimal cut-off

331 ≥ 2.5 derived in this current prospective ILD cohort. Notably, the CURB-65 score did not add
332 value to the ability of the NEWS-2 score to predict poor outcomes. In contrast, exploratory
333 analyses indicate there is some evidence of increased predictive ability on outcomes when
334 NEWS-2 and GAP scores are used in tandem. Overall, these findings from different centres
335 and patient populations suggest that the disease severity scores show promise in predicting
336 poor outcome following hospitalisation with acute respiratory deterioration.

337

338 As reported before the emergence of SARS-CoV-2, patients hospitalised with ARD-IPF had
339 a poor prognosis.^{4,23-25} The median survival in this cohort was 23 days, slightly shorter than
340 the survival times in the literature ranging between 1 and 4 months after AE-IPF.²⁶⁻²⁹ Whilst
341 in-hospital and 90-day mortality rates were significantly higher in the IPF group than the non-
342 IPF group, all admissions related to an ARD were associated with significant mortality; 24%
343 and 38% for 30- and 90-day mortality, respectively. Our in-hospital mortality data supports
344 early and frank discussions between patients/families and clinicians surrounding the high
345 mortality associated with ARD, even in the context of potentially 'treatable' causes e.g.
346 infection and pulmonary embolism. Furthermore, the high short-term mortality after
347 discharge may prompt clinicians to consider early discussions surrounding palliation and/or
348 transplantation in suitable candidates.

349

350 There were few admissions secondary to AE-ILD, which prevented further detailed analyses
351 of any differences in the mortality between AE-ILD and other parenchymal causes of ARD.
352 Teramachi *et al* showed 90-day mortality of AE-IPF patients was significantly higher than
353 ARD due to other parenchymal causes (46% (16/35) vs 17% (12/71) respectively;
354 $P=0.002$).¹⁴ It is not possible to ascertain fully to what extent healthcare access and patient
355 behaviour during the pandemic affected these outcomes. The Task Force for Lung Health

356 suggested that over a third of people with pre-existing lung problems felt pressure to avoid or
357 delay seeking treatment.³⁰ Hence, patients may have delayed presentation to hospital.
358 Alternatively, the emergence of a novel pathogen may have affected outcomes of patients
359 with ARD, either directly or indirectly through changes in the epidemiology of other acute
360 respiratory infection, treatment pathways or other aspects of patient healthcare provision. In
361 non-ILD patients hospitalised with SARS-CoV-2 infection, NEWS-2 correlates moderately
362 well with severe outcomes such as ITU admission, positive airway pressure support or death;
363 however, there were no such significant correlations for CURB-65 ($P>0.05$).³¹

364

365 This study has many strengths. It was undertaken as a prospective two site cohort study
366 which screened hospital admissions for signs/symptoms of acute respiratory disease. This
367 study therefore does not rely on ICD-10 coding or solely on data-linkage. There were
368 minimal missing data, and the study includes adults who lack capacity to consent through a
369 consultee and by specific authorisation to use certain data without consent, thereby ensuring
370 full ascertainment of ARD-ILD during this period. The medical records were linked with
371 community records to obtain detailed and accurate data for each study participant.

372

373 There are also some limitations of this study. First, we assessed ARD-ILD at both acute care
374 NHS hospitals in Bristol and 83% of this cohort is Caucasian; therefore, we cannot be sure
375 that results are generalisable to other patient populations. Second, we used vital statistics to
376 determine mortality, and did not ascertain the specific cause of death. Third, the number of
377 acute exacerbations in this cohort was low, we were therefore unable to confirm our previous
378 findings that mortality associated with ARD-ILD was high, irrespective of the underlying
379 cause for the deterioration. Lastly, it is difficult to determine whether healthcare access may
380 have affected time to hospitalisation and hence outcomes, as previously mentioned.

381

382 **CONCLUSION**

383 Simple illness severity scores may permit refinement of ARD management of ILD patients

384 and if survival to discharge is achieved, permit early discussion with patients, referral to

385 transplantation or palliative care planning as appropriate.

386

387 **REFERENCES**

- 388 1. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute
389 Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
390 *Am J Respir Crit Care Med*. 2016 Aug 1;194(3):265–75.
- 391 2. Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, et al. Burden
392 of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study.
393 *PLoS One*. 2017;12(1):e0166462.
- 394 3. Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients With
395 Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large
396 Cohort Analysis. *Chest*. 2016 May;149(5):1205–14.
- 397 4. Hyams C, Hettle D, Bibby A, Adamali HA, Barratt SL. Utility of illness severity scores
398 to predict mortality in patients hospitalised with respiratory deterioration of Idiopathic
399 Pulmonary Fibrosis. *QJM*. 2020 Jul 1;hcaa214.
- 400 5. Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, et al. Acute exacerbations
401 of progressive-fibrosing interstitial lung diseases. *Eur Respir Rev*. 2018 Dec
402 31;27(150):180071.
- 403 6. Southern BD. Patients with interstitial lung disease and pulmonary sarcoidosis are at high
404 risk for severe illness related to COVID-19. *Cleve Clin J Med*. 2020 Jun 18;
- 405 7. Esposito AJ, Menon AA, Ghosh AJ, Putman RK, Fredenburgh LE, El-Chemaly SY, et al.
406 Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A
407 Case-Control Study. *Am J Respir Crit Care Med*. 2020 Dec 15;202(12):1710–3.
- 408 8. Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome
409 of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An
410 International Multicenter Study. *Am J Respir Crit Care Med*. 2020 Dec 15;202(12):1656–
411 65.
- 412 9. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al.
413 Defining community acquired pneumonia severity on presentation to hospital: an
414 international derivation and validation study. *Thorax*. 2003 May;58(5):377–82.
- 415 10. Chang CL, Sullivan GD, Karalus NC, Mills GD, McLachlan JD, Hancox RJ. Predicting
416 early mortality in acute exacerbation of chronic obstructive pulmonary disease using the
417 CURB65 score. *Respirology*. 2011 Jan;16(1):146–51.
- 418 11. Smith MEB, Chiovaro JC, O’Neil M, Kansagara D, Quiñones AR, Freeman M, et al.
419 Early warning system scores for clinical deterioration in hospitalized patients: a
420 systematic review. *Ann Am Thorac Soc*. 2014 Nov;11(9):1454–65.
- 421 12. Smith GB, Prytherch DR, Meredith P, Schmidt PE. Early warning scores: unravelling
422 detection and escalation. *Int J Health Care Qual Assur*. 2015;28(8):872–5.
- 423 13. Kim I, Song H, Kim H, Park K, Kim SH, Oh S, et al. Use of the National Early Warning
424 Score for predicting in-hospital mortality in older adults admitted to the emergency
425 department. *Clinical and Experimental Emergency Medicine*. 2020 Mar 31;7:61–6.

- 426 14. Teramachi R, Kondoh Y, Kataoka K, Taniguchi H, Matsuda T, Kimura T, et al.
427 Outcomes with newly proposed classification of acute respiratory deterioration in
428 idiopathic pulmonary fibrosis. *Respir Med*. 2018 Oct;143:147–52.
- 429 15. ISRCTN - ISRCTN17354061: A pan-pandemic respiratory infection surveillance study
430 [Internet]. [cited 2021 Oct 6]. Available from: <https://www.isrctn.com/ISRCTN17354061>
- 431 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
432 data capture (REDCap)--a metadata-driven methodology and workflow process for
433 providing translational research informatics support. *J Biomed Inform*. 2009
434 Apr;42(2):377–81.
- 435 17. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future.
436 *Eur Respir Rev*. 2014 Jun;23(132):220–4.
- 437 18. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A
438 multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern*
439 *Med*. 2012 May 15;156(10):684–91.
- 440 19. Smith GB, Prytherch DR, Jarvis S, Kovacs C, Meredith P, Schmidt PE, et al. A
441 Comparison of the Ability of the Physiologic Components of Medical Emergency Team
442 Criteria and the U.K. National Early Warning Score to Discriminate Patients at Risk of a
443 Range of Adverse Clinical Outcomes. *Crit Care Med*. 2016 Dec;44(12):2171–81.
- 444 20. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute
445 Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
446 *Am J Respir Crit Care Med*. 2016 Aug 1;194(3):265–75.
- 447 21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating
448 characteristic (ROC) curve. *Radiology*. 1982 Apr 1;143(1):29–36.
- 449 22. Yamazaki R, Nishiyama O, Yoshikawa K, Saeki S, Sano H, Iwanaga T, et al.
450 Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in
451 patients with idiopathic pulmonary fibrosis. *Sci Rep*. 2021 Feb 16;11(1):3880.
- 452 23. Salonen J, Vähänikkilä H, Purokivi M, Kaarteenaho R. Causes of acute respiratory
453 hospitalizations predict survival in fibrosing interstitial lung diseases. *PLOS ONE*. 2020
454 Nov 30;15(11):e0242860.
- 455 24. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute
456 exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2007 Oct
457 1;176(7):636–43.
- 458 25. Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute
459 exacerbation of idiopathic pulmonary fibrosis. *European Respiratory Review* [Internet].
460 2018 Jun 30 [cited 2022 Jul 6];27(148). Available from:
461 <https://err.ersjournals.com/content/27/148/175050>
- 462 26. Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, et al.
463 Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial
464 pneumonia. *Respirology*. 2016 Nov;21(8):1431–7.

- 465 27. Cao M, Sheng J, Qiu X, Wang D, Wang D, Wang Y, et al. Acute exacerbations of
466 fibrosing interstitial lung disease associated with connective tissue diseases: a population-
467 based study. *BMC Pulmonary Medicine*. 2019 Nov 14;19(1):215.
- 468 28. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, for the IPFnet investigators.
469 Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in
470 clinical trials. *Respiratory Research*. 2013 Jul 13;14(1):73.
- 471 29. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic
472 pulmonary fibrosis: incidence, risk factors and outcome. *European Respiratory Journal*.
473 2011 Feb 1;37(2):356–63.
- 474 30. Over a third of people with lung conditions felt pressure to avoid or delay seeking
475 treatment during lockdown - British Lung Foundation [Internet]. Asthma + Lung UK.
476 2020 [cited 2022 Jul 6]. Available from: [https://www.blf.org.uk/taskforce/press-
477 release/over-a-third-of-people-with-lung-conditions-felt-pressure-to-avoid-or-delay-
478 seeking-treatment](https://www.blf.org.uk/taskforce/press-release/over-a-third-of-people-with-lung-conditions-felt-pressure-to-avoid-or-delay-seeking-treatment)
- 479 31. Arnold DT, Attwood M, Barratt S, Morley A, Elvers KT, McKernon J, et al. Predicting
480 outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study.
481 *Emerg Med J*. 2021 Jul;38(7):543–8.

482

483

484 **FIGURE LEGENDS**

485 **Figure 1. Adults hospitalised with acute respiratory deterioration of interstitial lung**
486 **disease**

487 (A) Flow diagram of study participants and (B) aetiology of acute respiratory deterioration of
488 Interstitial lung disease (ARD-ILD).

489 ARD; acute respiratory deterioration; AE-ILD, acute exacerbation of interstitial lung disease;
490 LRTI, lower respiratory tract infection; COVID-19, coronavirus disease 2019; HF, heart
491 failure.

492 +n=11 COVID-19 pneumonia, one aspiration pneumonia, one hospitalised pneumonia,
493 remainder deemed to be community acquired pneumonia

494 *including 3 with symptomatic COVID-19 but no CXR infiltrates

495 ^ unclassified – CT not performed and CRP <50.

496

497 **Figure 2: ARD-ILD survival curve analysis**

498 Kaplan Meier survival curves for (A) in-hospital and (B) 90-day mortality, for patients
499 admitted with ARD-IPF (green line) and non-IPF ARD-ILD (blue line).

500 **AUTHOR CONTRIBUTIONS**

501 CH, RW, PW, AF and SLB generated the research question and analysis plan. The data for
502 this study was collected by the AvonCAP Research Team, CH, RW, JR, MGG and ZSB. CH,
503 MGG, ZSB and RW verified the data. RW, CH, PW, AF and SLB undertook data analysis.
504 All authors were involved in the final manuscript preparation and its revisions before
505 publication. AF and SB provided oversight of the research.

506

507 **ACKNOWLEDGEMENTS**

508 The authors would like to acknowledge the Research Teams at North Bristol NHS and
509 University Hospitals Bristol and Weston NHS Trusts, including Helen Lewis-White, Diana
510 Benton, Anna Morley, Jade King and Nicola Manning. Furthermore, we would like to
511 acknowledge the significant contribution to the AvonCAP study made by Rachel Davies,
512 Adam Taylor, Mai Baquedano and the IT team, including Stuart Robinson, at North Bristol
513 NHS Trust.

514

515 **DATA SHARING**

516 The data used in this study are sensitive and cannot be made publicly available without
517 breaching patient confidentiality regulations. Therefore, individual participant data and a data
518 dictionary are not available to other researchers.

519

520 **DECLARATION OF INTEREST**

521 CH is Principal Investigator of the AvonCAP study, which is an investigator-led University
522 of Bristol study funded by Pfizer, Inc, and is currently a member of the BTS Pulmonary
523 Infection Specialty Advisory Group (SAG). AF is a member of the Joint Committee on
524 Vaccination and Immunization (JCVI) and chair of the World Health Organization European



525 Technical Advisory Group of Experts (WHO ETAGE) committee. In addition to receiving
526 funding from Pfizer as Chief Investigator for this study, he leads another project investigating
527 transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates The
528 other authors declare no competing interests.


529 **The AvonCAP Research Group**

AUTHOR	AFFILIATION
David Adegbite	Bristol Vaccine Centre, University of Bristol
Rupert Antico	Bristol Vaccine Centre, University of Bristol
Francesca Bayley	Bristol Vaccine Centre, University of Bristol
Beth Begier	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA
Maddalena Bellavia	North Bristol NHS Trust
Emma Bridgeman	Bristol Vaccine Centre, University of Bristol
Julia Brzezinska	Clinical Research and Imaging Centre, UHBW NHS Trust
James Campling	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA
Natalie Chang	Clinical Research and Imaging Centre, UHBW NHS Trust
Julie Cloake	Clinical Research and Imaging Centre, UHBW NHS Trust
Madeleine Clout	Bristol Vaccine Centre, University of Bristol
Pip Croxford	North Bristol NHS Trust
Gillian Ellsbury	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, UK
Bradford Gessner	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA
Niall Grace	Bristol Vaccine Centre, University of Bristol
Sharon Gray	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA
Oliver Griffiths	Clinical Research and Imaging Centre, UHBW NHS Trust
Charli Grimes	North Bristol NHS Trust
Lucy Grimwood	Bristol Vaccine Centre, University of Bristol
Zsolt Friedrich	North Bristol NHS Trust
Leah Fleming	Bristol Vaccine Centre, University of Bristol
Kazminder Fox	Clinical Research and Imaging Centre, UHBW NHS Trust
Milo Jeenes-Flanagan	Bristol Vaccine Centre, University of Bristol
Luis Jodar	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA
Johanna Kellett Wright	Clinical Research and Imaging Centre, UHBW NHS Trust
Jane Kinney	Bristol Vaccine Centre, University of Bristol
Robyn Heath	Clinical Research and Imaging Centre, UHBW NHS Trust
Kate Helliker	North Bristol NHS Trust
Robyn Huber	Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA
Amelia Langdon	Bristol Vaccine Centre, University of Bristol
Rajeka Lazarus	Clinical Research and Imaging Centre, UHBW NHS Trust
Sandi Nammuni Arachchge	Clinical Research and Imaging Centre, UHBW NHS Trust
Vicki Mackay	Clinical Research and Imaging Centre, UHBW NHS Trust
Robin Marlow	Bristol Vaccine Centre, University of Bristol
Zandile Maseko	North Bristol NHS Trust

Anya Mattocks	Bristol Vaccine Centre
Katie Maughan	Clinical Research and Imaging Centre, UHBW NHS Trust
Nicola Manning	Clinical Research and Imaging Centre, UHBW NHS Trust
Katarina Milutinovic	Clinical Research and Imaging Centre, UHBW NHS Trust
Konstantina Minou	Clinical Research and Imaging Centre, UHBW NHS Trust
Anna Morley	North Bristol NHS Trust
Taslima Mona	Clinical Research and Imaging Centre, UHBW NHS Trust
Claire Mitchell	Clinical Research and Imaging Centre, UHBW NHS Trust
Leigh Morrison	North Bristol NHS Trust
Bethany Osborne	Clinical Research and Imaging Centre, UHBW NHS Trust
Fiona Perkins	Clinical Research and Imaging Centre, UHBW NHS Trust
Tawassal Riaz	Clinical Research and Imaging Centre, UHBW NHS Trust
Gabriella Ruffino	North Bristol NHS Trust
Peter Sequenza	Bristol Vaccine Centre, University of Bristol
Lily Smart	Bristol Vaccine Centre, University of Bristol
Emma Scott	Clinical Research and Imaging Centre, UHBW NHS Trust
Jo Southern	Vaccines Medical Development, Scientific & Clinical Affairs, Pfizer Inc, UK
Seevakumar Suppiah	North Bristol NHS Trust
Zoe Taylor	Bristol Vaccine Centre, University of Bristol
Grace Tilzey	Clinical Research and Imaging Centre, UHBW NHS Trust
Anabella Turner	Clinical Research and Imaging Centre, UHBW NHS Trust
Gabriella Valentine	Bristol Vaccine Centre, University of Bristol
Marianne Vasquez	North Bristol NHS Trust
Rhian Walters	Clinical Research and Imaging Centre, UHBW NHS Trust
Lana Ward	North Bristol NHS Trust
Louise Wright	North Bristol NHS Trust

530

A**B**

A**B**